Flonoltinib for people with polycythemia vera
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new pill, flonoltinib, for people with polycythemia vera whose blood counts are hard to control and who have not responded well to or couldn't tolerate current treatments. The goal is to see if the pill can lower the number of red blood cells and reduce symptoms, potentially reducing the need for frequent blood removal procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have polycythemia vera and are resistant to or intolerant of standard treatments like hydroxyurea or interferon.
- You have needed blood removal (phlebotomy) recently, or your blood thickness (hematocrit) is still above 45% despite treatment.
- Your blood counts and liver/kidney function are within certain limits (will be checked with tests).
- You are able to care for yourself (ECOG score 0–2) and willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This trial is testing a new pill for people with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It aims to see if the drug can help manage the disease and offer a new treatment option for those who may have limited choices.
This trial tests a new oral medicine, flonoltinib maleate, to see if it can help reduce spleen size and improve symptoms in people with myelofibrosis, a type of blood disorder. The study enrolls patients who have not responded to other treatments or have not had JAK inhibitor therapy (or only briefly).
This trial tests a new tablet, Flonoltinib, for people with medium-to-high risk myelofibrosis whose prior JAK inhibitor treatment stopped working, caused side effects, or wasn't tolerated. The goal is to see if this new drug can help reduce spleen size and improve symptoms.
Hear when a new Polycythemia Vera (PV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.